Published in Neurology on January 22, 2014
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) | NCT03561402
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One (2014) 0.79
Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo. J Neuroinflammation (2015) 0.76
Human CD4(+) T-Cells: A Role for Low-Affinity Fc Receptors. Front Immunol (2016) 0.75
Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT. Ann Clin Transl Neurol (2014) 0.75
Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. BMC Neurol (2017) 0.75
Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics (2006) 10.83
GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics (2007) 6.63
Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A (2003) 6.49
Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell (2004) 5.59
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain (2003) 3.39
TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 3.04
Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol (2010) 2.55
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology (2004) 2.04
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet (2010) 1.73
Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol (2005) 1.73
A causal link between lymphopenia and autoimmunity. Immunol Lett (2004) 1.61
Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection. J Immunol (2006) 1.52
TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. J Clin Invest (2010) 1.45
CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. J Immunol (1993) 1.42
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology (2004) 1.34
T cell activation by TLRs: a role for TLRs in the adaptive immune response. Sci STKE (2007) 1.28
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A (2008) 1.27
Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics (2008) 1.21
T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol (2006) 1.13
Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis. Neurobiol Dis (2010) 1.09
Natural history of secondary-progressive multiple sclerosis. Mult Scler (2008) 1.02
Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax (1999) 1.02
Human autoreactive CD4+ T cells from naive CD45RA+ and memory CD45RO+ subsets differ with respect to epitope specificity and functional antigen avidity. J Immunol (2000) 0.96
Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. Clin Exp Immunol (2006) 0.87
Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS). J Neuroimmunol (2011) 0.87
Thymic involution and proliferative T-cell responses in multiple sclerosis. J Neuroimmunol (2010) 0.86
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Quantitative proteomics analysis of the secretory pathway. Cell (2006) 3.63
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Tools for visually exploring biological networks. Bioinformatics (2007) 3.20
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol (2007) 2.68
Associations with early-life socio-economic position in adult DNA methylation. Int J Epidemiol (2011) 2.67
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler (2010) 2.45
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med (2012) 2.36
Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res (2006) 2.12
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol (2011) 2.12
Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol (2006) 2.06
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 1.92
Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol (2004) 1.89
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Broad epigenetic signature of maternal care in the brain of adult rats. PLoS One (2011) 1.86
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol (2004) 1.76
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med (2014) 1.75
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol (2007) 1.73
Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia (2012) 1.73
Simultaneous identification of duplications and lateral gene transfers. IEEE/ACM Trans Comput Biol Bioinform (2011) 1.66
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth. J Neurosci Methods (2007) 1.59
Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res (2011) 1.58
Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58
Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res (2009) 1.58
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler (2012) 1.55
The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. J Neurosci (2012) 1.51
Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol (2010) 1.51
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Identifying regulatory subnetworks for a set of genes. Mol Cell Proteomics (2005) 1.48
TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol (2011) 1.47
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol (2011) 1.45
Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology (2013) 1.44
Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci (2005) 1.43
Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol (2007) 1.41
Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res (2007) 1.39
Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood (2006) 1.36
Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol (2004) 1.34
Microglia and multiple sclerosis. J Neurosci Res (2005) 1.34
Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases. AIDS Res Hum Retroviruses (2006) 1.34
Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol (2012) 1.32
Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res (2009) 1.32
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 1.27
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One (2010) 1.26
2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol (2012) 1.21
miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol (2013) 1.21
Neuromyelitis optica with hypothalamic involvement. Mult Scler (2005) 1.20
Determinants of human B cell migration across brain endothelial cells. J Immunol (2003) 1.19
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res (2010) 1.19
Lesion distribution in children with clinically isolated syndromes. Ann Neurol (2008) 1.17
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Pathogenesis of multiple sclerosis. Curr Opin Neurol (2005) 1.16
B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol (2008) 1.14
Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol (2009) 1.11
Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med (2003) 1.10
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol (2009) 1.10
Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol (2011) 1.10
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Cancer Res (2002) 1.10
PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem (2009) 1.09
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol (2005) 1.09
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res (2013) 1.08
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol (2010) 1.08
Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res (2007) 1.06
Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol (2006) 1.06
Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol (2008) 1.05
Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia (2007) 1.03
Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci (2008) 1.03
Multiple sclerosis vs acute disseminated encephalomyelitis in childhood. Pediatr Neurol (2003) 1.03
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health (2004) 1.02
Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab (2011) 1.02
Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci (2011) 1.02
Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler (2003) 1.01
Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res (2008) 1.01
Mapping cis-acting regulatory variation in recombinant congenic strains. Physiol Genomics (2006) 1.00
Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence. PLoS Pathog (2010) 1.00
From bench to MS bedside: challenges translating biomarker discovery to clinical practice. J Neuroimmunol (2012) 0.99
Detection of identity by descent using next-generation whole genome sequencing data. BMC Bioinformatics (2012) 0.99
The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. Med Decis Making (2002) 0.98